Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491056 | 0.81 | MEN1 (0.57) | ALDH1A1PKMKDM4EMEN1KMT2A | |
| SCHEMBL174384 | 0.80 | KDM4E (0.62) | ALDH1A1PKMKDM4E | |
| Hydrochloric Acid SCHEMBL540053 | 0.79 | KDM4E (0.60) | ALDH1A1PKMKDM4E | |
| Hydrochloric Acid SCHEMBL29442137 | 0.79 | KDM4E (0.60) | ALDH1A1PKMKDM4E | |
| SCHEMBL1491054 | 0.78 | GRIN2B (0.43) | GRIN2BGRIN1 | |
| SCHEMBL1491095 | 0.74 | KDM4E (0.53) | ALDH1A1PKMKDM4EMEN1KMT2A | |
| SCHEMBL1491108 | 0.74 | LMNA (0.55) | ALDH1A1PKMKDM4EKMT2A | |
| SCHEMBL29696195 | 0.74 | CYP19A1 (0.49) | ALDH1A1PKMKDM4EMEN1KMT2A | |
| SCHEMBL1491113 | 0.72 | ALDH1A1 (0.54) | ALDH1A1PKMKDM4EGRIN2BGRIN1 | |
| SCHEMBL1491102 | 0.72 | ALDH1A1 (1.00) | ALDH1A1PKMKDM4ECYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 3233/4885PKM 2177/4885KDM4E 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.